Varisacumab
Based on 1 Customer Validation
Varisacumab (R 84; GNR-011) is a fully humanized IgG1 monoclonal antibody targeting VEGF. Varisacumab specifically blocks the interaction between VEGF and VEGFR2, but does not interfere with the interaction between VEGF and VEGFR1. Varisacumab achieves effective anti-tumor and anti-angiogenic effects and can be used in the research of non-small cell lung cancer and pancreatic cancer.
For research use only. We do not sell to patients.
- Purity: 97.28%
- CAS No.: 1610010-60-0
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All VEGFR Isoforms
More
Biological Activity
Human IgG1 kappa
Human
|
VEGFR2 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Immobilized VEGF121 Protein, Human (120 a.a, HY-P7420) can bind Varisacumab. The EC50 for this effect is 12.18 ng/mL.
Chemical Information
-
CAS No. 1610010-60-0
-
Appearance Liquid
-
Color Colorless to light yellow
-
SMILES
[Varisacumab]
-
Synonyms
R 84 (antibody); GNR-011
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (255 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)